PALI - Why Is Gastrointestinal Disease-Focused Palisade Bio Stock Trading Higher Today? | Benzinga
Palisade Bio Inc (NASDAQ:PALI) shares are trading higher after the company announced the presentation of preclinical data of its lead asset, PALI-2108, at the Crohn’s & Colitis Congress.
The shares are trading higher to a heavy volume of over 84 million, compared to an average volume (100 day) of 288.181K, according to data from Benzinga Pro.
PALI-2108 is the company’s orally administered, locally acting colon-specific phosphodiesterase-4B (PDE4B) inhibitor prodrug in development for patients affected by moderate-to-severely active ulcerative colitis (UC).
Mitchell Jones, ...